Close
Achema

Pneumococcal Vaccines Aided By New Approach By Singapore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Numerous disease-causing bacteria like Streptococcus pneumoniae, happen to be encased in a sugar layer that is known as the capsular polysaccharide (CPS). This layer is often essential when it comes to infections.

In a discovery that can indeed be termed as ground-breaking by the scientists from the Yong Ling Lin School of Medicine of the National University of Singapore, the traits of the CPS that aid the bacteria so as to colonise the human respiratory track were pinpointed.
The study also showed that structures of the CPS capsule as well as its types of linkages and combinations, greatly matter in letting the bacteria attach better and survive on the lining of the upper and lower human respiratory tracts as well.

This inference can go on to shed more light on the CPS type range that will be a part of future vaccines since the current vaccines against S. pneumoniae do not cover the numerous types of CPS that are produced by the bacteria.

S. pneumoniae happens to be a major driver when it comes to septicaemia, pneumonia, as well as meningitis. To thwart the deadly infections, the pneumococcal vaccines are administered so as to stimulate the production of antibodies against the CPS.

That said, the bacteria can go on to manipulate their structure so as to evade the antibodies. This biochemical warfare results in more than a hundred kinds of CPSs that are produced by S. pneumoniae, which elevates the challenge when it comes to producing effective vaccines.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back